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Abstract. Current COVID-19 pandemic and previous SARS/MERS outbreaks have 
caused a series of major crises to global public health. We must integrate the large 
and exponentially growing amount of heterogeneous coronavirus data to better 
understand coronaviruses and associated disease mechanisms, in the interest of 
developing effective and safe vaccines and drugs. Ontologies have emerged to play 
an important role in standard knowledge and data representation, integration, 
sharing, and analysis. We have initiated the development of the community-based 
Coronavirus Infectious Disease Ontology (CIDO). As an Open Biomedical 
Ontology (OBO) library ontology, CIDO is an open source and interoperable with 
other existing OBO ontologies. In this article, the general architecture and the design 
patterns of the CIDO are introduced, CIDO representation of coronaviruses, 
phenotypes, anti-coronavirus drugs and medical devices (e.g. ventilators) are 
illustrated, and an application of CIDO implemented to identify repurposable drug 
candidates for effective and safe COVID-19 treatment is presented. 
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1. Introduction 
Coronavirus diseases pose major crises to public health. In addition to the current 
COVID-19 pandemic, Severe Acute Respiratory Syndrome (SARS) [1] and Middle East 
respiratory syndrome (MERS) [2] are two other severe HCoV diseases that have 
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occurred in the past two decades. More recently, the WHO declared the Coronavirus 
Disease 2019 (COVID-19) outbreak as a pandemic on March 11, 2020, when there were 
118,326 confirmed cases and 4,292 deaths. As of May 25, there have been over 5.5 
million confirmed cases and approximately 350,000 deaths globally.  
A major bottleneck for coronavirus disease research, however, is that valuable 
research data and knowledge are siloed in non-integratable and non-interoperable data 
repositories. Big data has the characteristics of 5 V’s: volume, veracity (i.e., quality of 
data), velocity, variety, and value [3]. In the era of Information Technology and big data, 
biomedical research has become data-intensive with increasingly large, complex, 
multidimensional, and diverse datasets generated. Knowledge is a special type of data 
that embodies awareness and understanding. Non-integrated and non-interoperable data 
and knowledge inhibit computer-assisted reasoning, which is the essence of Artificial 
Intelligence. To address this bottleneck, we can rely on computer-interpretable 
integrative and interoperable ontology.  
With that in mind, to study coronaviruses efficiently we have initiated the 
development of a community-based interoperable Coronavirus Infectious Disease 
Ontology (CIDO) for standardized and integrative coronavirus disease representation, 
integration, and analysis. This manuscript provides details on current status of CIDO 
development and applications.    
2. Methods  
2.1. Coronavirus disease-related data collection 
The coronavirus disease related data were collected from the literature and openly 
available databases. We have focused on coronavirus and host taxonomy data, phenotype, 
drug, and vaccine data.   
2.2. Ontology development  
CIDO development followed the OBO Foundry ontology development principles [4] and 
the eXtensible Ontology Development (XOD) strategy [5]. The CIDO development 
started with the reuse and alignment of terms and relations from existing ontologies using 
the Ontofox tool [6]. We used the Basic Formal Ontology (BFO) [7], Chemical Entities 
of Biological Interest (ChEBI) [8], Human Disease Ontology (DOID) [9], Human 
Phenotype Ontology (HPO) [10], Infectious Disease Ontology (IDO) [11], etc. The 
Protégé-OWL editor was used for ontology editing.   
2.3. CIDO status, source code, deposition, and license 
CIDO has been accepted as an OBO library ontology 
(http://www.obofoundry.org/ontology/cido.html). CIDO source code is freely available 
on the GitHub website https://github.com/CIDO-ontology/cido. The source code uses 
the license CC-BY. CIDO has been deposited to the Ontobee ontology repository 
(http://www.ontobee.org/ontology/CIDO) the BioPortal repository 
(https://bioportal.bioontology.org/ontologies/CIDO), and the OLS repository 
(https://www.ebi.ac.uk/ols/ontologies/cido).    
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2.4. CIDO representation demonstrations and drug repurposing use case  
In this manuscript, we provide demonstrations of different CIDO ontological 
representations of coronaviruses, drugs, vaccines, and medical devices. We also show 
how CIDO can be used to support rational design for drug repurposing. Description 
Logic (DL) and SPARQL queries are used in Protégé–OWL editor for ontology content 
query.   
3. Results  
3.1. High level structure   
Figure 1 lays out the high-level hierarchical structure of CIDO, as well as the various 
ontologies which it imports. Abbreviations in parentheses indicate an entity source 
ontology, and red text indicates terms introduced by CIDO:  
 
Figure 1. Top level hierarchical structure of CIDO. Abbreviations not defined earlier: GO – Gene 
Ontology, NCBITaxon – NCBI Taxonomy Ontology, OBI – Ontology for Biomedical Investigations, OGMS 
– Ontology for General Medical Science, OHPI – Ontology of Host-Pathogen Interaction, OPMI – Ontology 
of Precision Medicine and Investigation.  
 
As illustrated above, CIDO uses the Basic Formal Ontology (BFO) as the top-level 
ontology. BFO has been approved to become ISO/IEC standard 21838. BFO contains 
two branches, ‘continuant’ and ‘occurrent’. The ‘continuant’ represents time-
independent entities such as material entity, and the ‘occurrent’ represents time-related 
entities such as process. BFO has been adopted by >300 ontologies. BFO provides us a 
mechanism to reuse and integrate with these many ontologies without interoperability 
issues, and will ultimately facilitate CIDO becoming a standard widely-used ontology 
for coordinating and integrating coronavirus research.  
Figure 2 describes the general CIDO design pattern that lays out the relations among 





Figure 2. Design pattern of CIDO for logically representing and linking different components related to 
coronavirus disease.   
One central term in CIDO is ‘COVID-19 disease process’ (Figure 2), which is 
defined as a subclass of ‘disease process’, which is defined as a subclass of ‘pathological 
bodily process’ (OGMS_0000061).  The ‘COVID-19 disease process’ has many features 
including those defined using the following axioms:  
- ‘occurs in’ some animal 
- ‘occurs in’ some lung, where lung is part of animal.  
- ‘caused by infection with’ some SARS-CoV-2 
- realizes some ‘COVID-19 disease’, which is a disposition defined in Human 
Disease Ontology (DOID).  
Based on the “all-some rule” in ontology [12], the axiom (‘occurs in’ some lung) 
means that every COVID-19 disease process occurs in some lung. We know that the 
disease can also occur in other organs such as kidney and brain; however, the occurrence 
in kidney or brain does not always happen. In this case, we can use the relation 
‘susceptibly occurs in’, which represents a susceptibility of the occurrence rather than an 
assurance.   
In addition, ‘COVID-19 vaccine’ ‘immunizes against disease process’ the ‘COVID-
19 disease process’, where the relation is a Vaccine Ontology (VO) relation (Figure 2). 
Furthermore, ‘COVID-19 drug’ ‘is substance that treats’ the ‘COVID-19 disease 
process’, and here the relation is a Relation Ontology (RO) term.  
Instead of directly using the disposition term ‘COVID-19 disease’, we chose to use 
‘COVID-19 disease process’ due to multiple reasons. First, the relation ‘occurs in’ only 
links a process to an anatomic entity (e.g., lung), and it cannot link a disposition to an 
anatomic entity. The relation ‘caused by infection with’ is also defined to link a 
pathological process (not a disposition) with a pathogen. Furthermore, the vaccines and 
drugs are used for an existing disease process instead of a disease disposition. Meanwhile, 
the ‘COVID-19 disease’ disposition is realized in the ‘COVID-19 disease process’, 
which closely links the two terms together.  
Figure 2 also lays out the genes, cells, quality types (e.g., phenotypes, age) and their 
relations with each other and other entities in CIDO. For example, human ACE2 gene, 
which encodes for the Angiotensin I Converting Enzyme 2 (ACE2), is a receptor of the 
SARS-CoV-2 S protein. The ACE2-S binding in the epithelial cells of the lung would 
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stimulate a list of host genes up- or down-regulated in the cells, which may further 
contribute to the disease development.  
3.2. Classification of coronaviruses, hosts, and host phenotypes   
CIDO includes taxonomic representations of coronaviruses and hosts, and the 
phenotypes shown in coronavirus patients. Figure 2A represents the taxonomic hierarchy 
of representative coronaviruses. SARS-CoV and SAR-CoV-2 belong to the Sarbecovirus, 
a subclass of Betacoronavirus genus. MERS-CoV belongs to Merbecovirus subgenus 
under the same Betacoronavirus genus. Four human coronavirus strains (229E, NL63, 
HKU1, and OC43) cause mild common colds in humans, and they belong to different 
taxonomic locations compared to SARS-CoV, SARS-CoV-2, and MERS-CoV. Figure 
2B shows the common phenotypes shown in COVID-19 patients, including fever, chills, 
cough, shortness of breath (dyspnea), loss of smells and taste, etc. These terms have all 
been extracted from NCBITaxon and HPO and imported to CIDO.  
 
  
Figure 3.  Ontological representation of representative coronaviruses and COVID-19 phenotypes.  
(A) NCBITaxon representation of the hierarchy of representative coronaviruses. (B) HP representation of 
common phenotypes shown in COVID-19 patients. These hierarchical terms are imported to CIDO.  
3.3. Anti-coronavirus drug classification  
Extending our previous preprint work [13], we collected 136 anti-coronavirus drugs, 
including 26 coronavirus protein-specific monoclonal or polyclonal antibody drugs and 
110 general purpose drugs. These drugs have been experimentally verified in vivo or in 
vitro to be effective against the infections of various human coronaviruses including 
SARS-CoV, MERS-CoV, and SARS-CoV-2.  
We have mapped all these drugs to three ontologies: ChEBI [8], National Drug File 
– Reference Terminology (NDF-RT) [14], and the Drug Ontology (DrON) [15]. The 
subsets of these ontologies that contain the mapped drugs and their related characteristics 
were then extracted and imported to CIDO using the Ontofox tool [6].    
 6
Through the mechanism of Emergency Use Authorization (EUA), FDA has 
authorized two COVID-19 drugs for for the emergency treatment of COVID-19 patients: 
Remdesivir drug (https://www.fda.gov/media/141477/download) and COVID-19 
Convalescent Plasma (CCP) (https://www.fda.gov/media/137566/download). The 
following axiom defines the usage of Remdesivir and CCP for treating COVID-19:  
‘is substance that treatments’ some ‘COVID-19 disease process’   
The following axiom represents the relation between the drug ‘Remdesivir drug’ 
and its active ingredient:  
‘has active ingredient’ some remdesivir 
As defined in ChEBI, remdesivir (http://purl.obolibrary.org/obo/CHEBI_145994) 
has many properties such as the antiviral role and anticoronaviral agent role.    
3.4. Anti-coronavirus vaccine representation in CIDO  
In another recent study published in a journal article [17], we reported our COVID-19 
vaccine design using reverse vaccinology and machine learning. This study collected 44 
vaccine candidates experimentally verified to be effective against coronavirus challenges 
in laboratory animal models and/or used in clinical trials. The Vaccine Ontology (VO) 
[18] has been used to represent these vaccines. The VO-represented terms and relations 
were then imported to CIDO (data not shown). Furthermore, we have used CIDO and 
other ontologies including the Ontology of Adverse Events (OAE) to systematically 
examine the adverse events associated with SARS/MERS/COVID-19 vaccine 
candidates, and found differential profiles in different types of vaccines (data not shown).    
3.5. Medical device for COVID-19 treatment  
During this unprecedented time of COVID-19 pandemic, due to the rapid spread of 
SARS-CoV-2, the control of the pandemic requires large amounts of medical devices in 
all healthcare settings, especially the nursing homes and or long-term care facilities 
where the most vulnerable population lives in high density. A medical device is any 
device intended to be used for medical purposes. The medical devices used for the 
pandemic include diagnosis testing kits, ventilators, and personal protective equipment 
(PPE) for medical use such as surgical masks, face shields, respirators, gowns, gloves 
etc. In the USA, the FDA is responsible for regulating medical devices used to diagnose, 
prevent and treat COVID-19. The NIH has also developed COVID-19 treatment 
guidelines to inform clinicians how to care for patients with COVID-19 
(https://www.covid19treatmentguidelines.nih.gov).   
Some COVID-19 patients may develop acute respiratory failure and require 
ventilatory support. As a specific use case, we focus the ontological representation on 
ventilators. A ventilator is defined as a machine that supports breathing when a person is 
unable to breathe enough on their own. The modern ventilator technology has evolved 
to enable a single device to operate in numerous modes, from basic continuous positive 
pressure (CPAP and bi-level PAP) to traditional pressure and volume ventilator modes. 
As a complicated machine, the modern ventilator system includes an operator interface 
where parameters will be set for proper management of the automatic ventilation 
supported by a mechanical ventilator. The central part of the ventilator is like a “black 
box”. The output of the ventilator can be measured and monitored to fit the patient’s 
condition. We developed a framework to demonstrate how CIDO models the entities 




Figure 4. Medical device design pattern for COVID-19 treatment. Mechanical ventilator is used as an 
example for the ontology modeling here.  
A ‘mechanical ventilator’ is a subclass of ‘ventilator’, which is a subclass of 
‘medical device’. The function of the ‘ventilator’ is to ‘deliver mixed gas into lung’. 
Multiple entities involved in a ‘mechanical ventilator operation’ process: a ‘mechanical 
ventilator’, a clinical ‘ventilator operator’, a ‘patient’ and the preset parameter of ‘tidal 
volume’. As a planned process, the operation of the mechanical ventilator aims to achieve 
the objective of assisting patient’s breathing that ‘is about treating’ the ‘acute respiratory 
failure disease process’, a pathological process that a ‘COVID-19 patient’ may be 
susceptible to. Note that the low tidal volume (4–8 mL/kg of predicted body weight) is 
an important parameter for the mechanical ventilation operation in the case of caring 
acute respiratory failure without damaging the lung 
(https://www.covid19treatmentguidelines.nih.gov/critical-care/).   
3.6. Statistics of CIDO    
As of August 30, 2020, CIDO has 6,758 terms, including imported terms from over 40 
existing ontologies. CIDO includes 190 CIDO-specific terms and hundreds of newly 
generated axioms that link different entities. The detailed statistics of CIDO is available 
at the Ontobee website: http://www.ontobee.org/ontostat/CIDO.   
3.7. Use cases of CIDO  
CIDO can be applied for many use cases. Below we will focus on drug repurposing 
demonstration and then introduce a few other use cases.   
Drug repurposing is a strategy to identify new uses for approved drugs that are 
outside the scope of the original medical indication. We previously identified 110 anti-
coronavirus drugs [13], most of which were not originally targeted for COVID-19 
treatment. We hypothesize that some of these drugs could be repurposed for treating 
COVID-19 patients. To address this hypothesis, we performed ontology-based 
bioinformatics analysis with the assumption that ontology-formatted computer-
interpretable results provided us a new way to identify more scientific insights. As shown 
in Figure 5, a DL query of CIDO identified 6 chemical compounds that have the antiviral 
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agent role and antimalarial role and has been found effective against the infection of 
SARS-CoV, SARS-CoV-2, or MERS-CoV. Our further analysis found that 3 out of these 
6 chemicals (amodiaquine, chloroquine, hydroxychloroquine) all have the role of 
inhibiting viral entry to host cells, and all these three chemicals are all under the class of 
quinolines. Furthermore, among these anticoronavirus chemicals, a query to find an 
entity having all of antiviral, antimalarial, and anti-inflammatory agent roles retrieved 
only one chemical compound - amodiaquine (Figure 6).  
 
Figure 5. DL query of potential drugs for potential COVID-19 treatment. (A) DL query of chemicals 
that have two roles (antiviral agent role and antimalarial role). (B) DL query of chemicals that have three roles 
including the two roles above and the anti-inflammatory agent role.  
CIDO is also being used in many other applications. For example, CIDO is being 
used by OHNLP (http://www.ohnlp.org/), the Open Health Natural Language Processing 
(NLP) Consortium aimed to promote clinical COVID-19 data NLP. The OHNLP 
COVID-19 research is also an effort of the National COVID Cohort Collaborative (N3C) 
program (https://ncats.nih.gov/n3c). CIDO has also been applied to support COVID-19 
vaccine study and semantic calculation and prediction.    
 
4. Discussion 
This manuscript introduces the initial development and applications of the community-
based Coronavirus Infectious Disease Ontology (CIDO). Our study demonstrates that 
CIDO provides an ideal platform to integrate important data needed to research different 
coronavirus disease-related entities such as viruses, phenotypes, drugs, vaccines, medical 
devices (e.g. ventilators),), supporting integrative analysis of COVID-19 and other 
human coronavirus diseases.  
We provide one CIDO use case concerning drug repurposing for COVID-19 
treatment. Despite extensive research and clinical trials, we as of now have found only 
one potentially effective therapy for COVID-19, Remdesivir [19]. Our ontology-based 
analysis provides a new strategy for rational drug repurposing design (Figure 4), 
complementing others [20, 21]. Eight active drug chemicals were found to have antiviral 
and antimalarial roles, and amodiaquine was found to not only have these two roles but 
also an additional anti-inflammatory role. Similar to chloroquine, Amodiaquine is a 4‐
aminoquinoline that has been used widely to treat and prevent uncomplicated malaria 
[22]. A comparative study showed that amodiaquine is more effective than chloroquine 
in the treatment therapy of falciparum malaria in Kenya [22]. It has also been 
recommended that combining amodiaquine with artesunate to reduce the risk of drug 
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resistance [23]. The performance of amodiaquine for possible COVID-19 treatment 
deserve further evaluation [24].  
An ongoing CIDO development is to model and represent the mechanisms of the 
molecular and cellular interaction between the hosts and coronaviruses. Such modeling 
will provide the foundation for our rational drug repurposing and vaccine development. 
In our drug preprint study [13], we extracted and analyzed the interactions between anti-
coronavirus drugs and their target proteins. These anti-coronavirus drugs were identified 
to be effective against coronavirus infections in vitro or in vivo. It is likely that some of 
the drug targets participate in active host-SARS-CoV-2 interactions leading to severe 
COVID-19 disease outcomes. Deeper modeling and representation of the intricate host-
virus-drug interactions would help us in better drug repurposing analysis.  
Being a “community-based” ontology, CIDO is committed to serve the community. 
CIDO is created to be open and freely available for the community to use. It is an 
interoperable ontology that reuses and interlinks to existing ontologies and resources. 
We also expect that the community gets involved in its development, and we are always 
ready to accept new ideas and critiques. 
In future work we will use CIDO as a platform to standardize different coronavirus 
research-related metadata types and apply them for the standardization and enhanced 
analysis of specific conditions defined in different experimental and clinical studies, and 
how these conditions would affect the disease outcomes. We will also identify and 
develop more applications tools that implementing CIDO for different purposes. More 
researchers and developers are welcome to join our community-based effort to advance 
the CIDO ontology and its applications.  
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